Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study
Open Access
- 25 July 2025
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 27123
Abstract
This study was designed to assess the safety and efficacy of Sintilimab plus Lenvatinib in combination with transarterial chemoembolization (TACE) and subsequent radiofrequency ablation (RFA) in the treatment of unresectable hepatocellular carcinoma (HCC). A retrospective data analysis was conducted on 21 patients diagnosed with HCC at Yibin First People's Hospital, between February 2021 and July 2022. These patients met the eligibility criteria and underwent TACE followed by RFA. After the first TACE, patients received maintenance therapy with Sintilimab and Lenvatinib until the occurrence of intolerable toxicity, disease progression, or demise. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The efficacy evaluation revealed a complete response (CR) in 7 patients (33.33%), a partial response (PR) in 13 (61.91%), and a stable disease (SD) in 1 (4.76%). The patients had a median follow-up duration of 29.4 months (95% CI, 24.67-34.14), with a median PFS of 17.3 months (95% CI, 5.84-28.76). The median OS was not reached (NR), with a 1-year OS rate of 95.24% and a 2-year OS rate of 75.89%. Tumor recurrence and metastasis occurred in 15 patients (71.43%), oligoprogression in 8 patients (38.90%) and extensive progression in 7 patients (33.33%), which were associated with the median OS duration of NR and 26.03 months (95%CI 17.48-34.59), respectively (P = 0.024). In terms of treatment safety, 95.24% (20 cases) of patients experienced treatment-related adverse events (AEs), mainly mild to moderate severity. Notably, 10 patients (47.62%) encountered at least one grade 3 or higher AEs, leading to treatment discontinuation in 2 patients due to severe side effects. The clinical efficacy and safety of Sintilimab plus Lenvatinib in combination with TACE followed by RFA has been shown to be promising in the treatment of unresectable HCC. These results suggested that this combined treatment strategy may be an effective therapeutic approach. Furthermore, patients with oligoprogression after initial treatment exhibited a more favorable prognosis, indicating a need for further exploration and validation by studies with larger sample sizes.Keywords
Funding Information
- Health Commission of Sichuan Province Medical Science and Technology Program (24WSXT074)
- National Anti-Tumor Drug Surveillance System of National Cancer Center (DSS-YSF-202311)
- Wu Jieping Medical Foundation (320.6750.2022-01-11)
This publication has 34 references indexed in Scilit:
- Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapyCancer Treatment Reviews, 2019
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion StudyClinical Cancer Research, 2019
- Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment StrategyLiver Cancer, 2017
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinomaJournal of Hepatology, 2017
- Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancerJournal of Translational Medicine, 2017
- A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinomaAnnals of Surgical Treatment and Research, 2014
- Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinomaHepatology, 2012
- Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysisLiver International, 2010
- Risk Factors and Prognostic Factors of Local Recurrence after Radiofrequency Ablation of Hepatocellular CarcinomaJournal of the American College of Surgeons, 2008
- A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumorsThe American Journal of Surgery, 2007